Fan-Ngai-Hung I, Lung K-C, Tso EY-K, Liu R, Chung TW-H, Chu M-Y, et al.. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet 2020;395:30 de mayo. [Ref.ID 103649]

Song HJ, Jiang X, Henry L, Nguyen MH, Park H. Proton pump inhibitors and risk of liver cancer and mortality in patients with chronic liver disease: a systematic review and meta-analysis. Eur J Clin Pharmacol 2020;76:851-66. [Ref.ID 103643]

Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, et al. for the ACTT-1 Study Group Members. Remdesivir for the treatment of covid-19 — Preliminary report. N Engl J Med 2020:22 de mayo. [Ref.ID 103631]

Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q, Hu Y, Luo G, et al.. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020;395:29 de abril. [Ref.ID 103630]

Ferner RE, Aronson JK. Chloroquine and hydroxychloroquine in covid-19. BMJ 2020;369:8 de abril. [Ref.ID 103595]

Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, Feldt T, Green G, Green ML, Lescure F-X, Nicastri E, Oda R, et al.. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med 2020:10 de abril. [Ref.ID 103581]

Simon TG, Duberg A-S, Aleman S, Chung RT, Chan AT, Ludvigsson JF. Association of aspirin with hepatocellular carcinoma and liver-related mortality. N Engl J Med 2020;382:12 de marzo. [Ref.ID 103565]

Dimmitt SB, Stampfer HG. Polypill for prevention of cardiovascular diseases. Lancet 2020;395:413-4. [Ref.ID 103520]

Schuster BC, Brhlikova P, Heath J, McGettigan P. The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011–2018. PLOS Medicine 2019;16:10 de septiembre. [Ref.ID 103247]

Roshandel G, Khoshnia M, Poustchi H, Hemming K, Kamangar F, Gharavi A, Ostovaneh MR, Nateghi A, Majed M, Navabakhsh B, Merat S, Pourshams A, Nalini M, Malekzadeh F, Sadeghi M, Mohammadifard N, Sarrafzadegan N, Naemi-Tabiei M, Fazel A, Brennan P, Etemadi A, Boffetta P, Thomas N, Marshall T, Cheng KK, Malekzadeh R. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial. Lancet 2019;394:24 de agosto. [Ref.ID 103246]

Rathi S, Kumar P. Drug-induced liver injury — Types and phenotypes. N Engl J Med 2019;381:3 de octubre. [Ref.ID 103189]

Anónimo. Hepatitis C medicines (Mavyret, Zepatier, and Vosevi): Drug Safety Communication - Due to rare occurrence of serious liver injury in some patients with advanced liver disease. FDA MedWatch alert 2019:28 de agosto. [Ref.ID 103166]

Jeong S, Tchoe HJ, Shin JY. All-cause mortality associated with tramadol use: a case-crossover study. Drug Saf 2019;42:junio. [Ref.ID 103119]

Richman IB, Ross JS. Weighing the harms and benefits of using statins for primary prevention: raising the risk threshold. Ann Intern Med 2018:4 de diciembre. [Ref.ID 102877]

Diallo T, Adjobimey M, Ruslami R, Trajman A, Sow O, Baah JO, Marks GB, Long R, Elwood K, Zielinski D, Gninafon M, Wulandari DA, Apriani L, Valiquette C, Fregonese F, Hornby K, Li P-Z, Hill PC, Schwartzman K, Benedetti A, Menzies D. Safety and side effects of rifampin versus isoniazid in children. N Engl J Med 2018;379:2 de agosto. [Ref.ID 102756]

Menzies D, Adjobimey M, Ruslami R, Trajman A, Sow O, Kim H, Baah JO, Marks GB, Long R, Hoeppner V, Elwood K, Al-Jahdali H, Gninafon M, Apriani L, Koesoemadinata KE, Kritski A, Rolla V, Bah B, Camara A, Boakye I, Cook VJ, Goldberg H, Valiquette C, Hornby K, Dion-M-J, Li P-Z, Schwartzman K, Benedetti A. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. N Engl J Med 2018;379:2 de agosto. [Ref.ID 102755]

Samper E. ¿Y por qué no una farmacéutica pública?. eldiario.es 2018:19 de abril. [Ref.ID 102705]

Anónimo. Acide obéticholique et cholangite biliaire primitive. Prescrire 2018;38:326-7. [Ref.ID 102652]

Anónimo. Flupirtine: Serious liver problems. European Union. WHO Drug Information 2018;32:21. [Ref.ID 102625]

Anónimo. Artemisia annua soft gel capsules: Reports of liver damage. New Zealand. WHO Drug Information 2018;32:20. [Ref.ID 102624]